最新刊期

      ZHANG Kaiying, YANG Zhengjun, ZHAO Yiyang, QIAN Zhengyi, LING Yihong, WEI Xiaoli

      DOI：10.11714/jsysu.med.YX20260023
      摘要：ObjectiveTo investigate the clinicopathological features， molecular profile， treatment response， and prognosis of SMARCA4 （BRG-1） and SMARCB1 （INI-1）-deficient undifferentiated tumors of the digestive system， aiming to enhance the understanding of this rare and highly aggressive molecular subtype.MethodsThis study is a single-center retrospective analysis. We included 9 cases of malignant digestive system tumors with loss of BRG-1 （SMARCA4） expression and 3 cases with loss of INI-1 （SMARCB1） expression， all pathologically confirmed at Sun Yat-sen University Cancer Center between April 2022 and December 2025. By reviewing clinical data， histological morphology， immunohistochemistry （testing for SMARCA4， SMARCB1， epithelial， mesenchymal， neuroendocrine markers， and mismatch repair proteins） and next-generation sequencing （NGS） results from 5 cases， we systematically summarized their clinicopathological and molecular characteristics， treatment strategies， and survival outcomes.Results​ Among the 12 patients， 6 were male and 6 were female， with a median age of 62 （44-70） years. 9 cases exhibited SMARCA4 deficiency， and 3 cases exhibited SMARCB1 deficiency. Tumors originated in the stomach （5 cases）， colon （3 cases）， pancreas （1 case）， with the primary site unknown in 3 cases. 9/12 of patients presented with stage Ⅳ disease at initial diagnosis. The histology predominantly showed undifferentiated carcinoma， with 1 case of poorly differentiated carcinoma. The tumor cells were epithelioid with significant atypia. Epithelial markers （e.g. CKpan） were often lost or markedly decreased， while vimentin could be positive. All 9 cases tested for MMR status were mismatch repair proficient （pMMR）， and the Ki-67 proliferation index was high ［median 80% （60%-90%）］. A discordance was observed between IHC findings and NGS results in the 5 sequenced cases. The NGS profiling revealed frequent co-occurring mutations， including TP53， KRAS， and NRAS， with no germline mutations identified.The median follow-up time was 277 （55-867） days. 9 of the 12 patients presented with stage Ⅳ disease at the time of initial diagnosis. Among 3 newly diagnosed patients without metastasis who received treatment， 2 achieved prolonged recurrence-free survival. Patients with advanced disease at initial diagnosis primarily underwent platinum-based chemotherapy or combination regimens， yet their prognosis was generally poor， with a median overall survival of 60 （45-541） days， ranging from 16 to 867 days. Notably， several patients who received chemotherapy combined with targeted therapy and immunotherapy achieved extended survival.ConclusionSMARCA4/SMARCB1-deficient undifferentiated tumor of the digestive system is a distinct molecular subtype characterized by high aggressiveness and poor prognosis， predominantly affecting middle-aged and elderly individuals. Diagnosis relies on the immunohistochemical loss of BRG-1 or INI-1 proteins. While no standard of care currently exists， treatment often refers to regimens for adenocarcinoma of the primary site. Combined immunotherapy and targeted therapy may offer potential benefits， warranting further validation in large-scale prospective studies.  
      关键词：BRG-1;INI-1;SWI/SNF complex;undifferentiated tumor of the digestive system;clinicopathological features   
      0
      |
      0
      |
      0
      <HTML>
      <L-PDF><Meta-XML>
      <引用本文> <批量引用> 154773211 false
      更新时间：2026-04-17

      LIU Xinran, JIE Huiying, SU Shanni, ZHOU Canquan

      DOI：10.11714/jsysu.med.YX20260039
      摘要：ObjectiveTo investigate the chromosomal characteristics of blastocysts and pregnancy outcomes in patients with polycystic ovary syndrome （PCOS）， and to analyze the impact of PCOS on embryonic aneuploidy rate and the risk of miscarriage.MethodsThe retrospective cohort study was conducted on the preimplantation genetic testing（PGT） in the First Affiliated Hospital of Sun Yat-sen University， including cycles of PGT for aneuploidy（PGT-A） and PGT for monogenic disorders（PGT-M）. The 191 PCOS cycles（PCOS group） were matched with 564 control cycles（control group） using propensity score matching. The oocyte and embryo viability， chromosomal testing results of blastocysts， and cumulative clinical outcomes were compared between two groups. Subgroup analysis was performed by stratifying PCOS patients based on oocyte retrieval （>20 vs. ≤20）. And the pregnancy outcomes after euploid embryo transfer were compared under different levels of ovarian response.ResultsPCOS group showed a significantly higher rate of aneuploidy per blastocyst compared to control group （21.8% vs. 19.0%， P=0.044）. Clinically， the overall miscarriage rate in the PCOS group was significantly higher than control group （16.6% vs. 10.3%， P=0.039）， even after euploid embryo transfer （17.2% vs. 10.0%， P=0.019）. In the PCOS subgroup with > 20 oocytes ， the miscarriage rate following euploid embryo transfer was dramatically increased compared to control group （21.4% vs. 6.7%， P=0.001）， accompanied by higher risks of early miscarriage （15.7% vs. 5.7%， P=0.011）. Conversely， the PCOS subgroup with ≤ 20 oocytes showed outcomes comparable to control group.ConclusionsPatients with PCOS exhibit a significantly higher rate of blastocyst aneuploidy compared to the control group. Furthermore， PCOS is associated with a marked increase in miscarriage rates following blastocyst transfer， even with euploid embryos， particularly among patients with high ovarian response.  
      关键词：polycystic ovary syndrome;preimplantation genetic testing;aneuploid embryo;embryo transfer;miscarriage   
      3
      |
      5
      |
      0
      <HTML>
      <L-PDF><Meta-XML>
      <引用本文> <批量引用> 154704900 false
      更新时间：2026-04-16

      SHAO Li, TAO Ke, WEI Li, LI Juanli, SHI Zhizhi, QIAO Shugui, WANG Shaokang

      DOI：10.11714/jsysu.med.YX20260027
      摘要：ObjectiveTo investigate the protective effect of ellagic acid （EA） against bleomycin （BLM）-induced pulmonary fibrosis and associated pulmonary function impairment in mice， and to elucidate its relationship with the regulation of the interleukin（IL）-17/ nuclear factor （NF）-κB/ matrix metalloproteinase （MMP）9 signaling axis.MethodsA pulmonary fibrosis model was established in male C57BL/6J mice via intratracheal BLM injection. Interventions included IL-17 neutralizing antibody， Ixekizumab， SB-3CT， PDTC， or EA were used to modulate the IL-17/NF-κB/MMP9 signaling axis. Pathological changes in lung tissue were observed via HE， Masson， and Sirius red staining. Pulmonary function was assessed using a pulmonary function test （PFT）. Western blot and qRT-PCR were employed to detect related protein and gene expression. Network pharmacology was utilized to predict the potential targets of EA. A protein-protein interaction （PPI） network was constructed using the STRING database and Cytoscape. Molecular docking was performed to validate the binding capability of EA to core targets.ResultsBLM successfully induced obvious pulmonary fibrosis and lung dysfunction in mice， significantly elevating the level of the pro-inflammatory cytokine IL-17. This was associated with the activation of the transcription factor NF-κB p65， leading to the upregulation of the pro-fibrotic factor MMP9. Inhibition of the IL-17/NF-κB/MMP9 signaling axis markedly alleviated the degree of pulmonary fibrosis. EA intervention significantly suppressed the BLM-induced increase in IL-17， blocked the activation of the NF-κB/MMP9 pathway， and consequently reduced lung fibrotic lesions and improved pulmonary function.ConclusionEA may effectively ameliorate BLM-induced pulmonary fibrosis and lung dysfunction in mice， likely by inhibiting the inflammatory and fibrotic responses mediated through the IL-17/NF-κB/MMP9 signaling pathway.  
      关键词：pulmonary fibrosis;ellagic acid;bleomycin;IL-17;signaling pathway   
      26
      |
      89
      |
      0
      <HTML>
      <L-PDF><Meta-XML>
      <引用本文> <批量引用> 153051303 false
      更新时间：2026-03-25
    0